ETV6 and PDGFRB: A license to fuse

Haematologica

Volumn 92, Issue 2, 2007, Pages 145-147

  Lierman, Els ^a   Cools, Jan ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; TRANSCRIPTION FACTOR ETV6; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; REPRESSOR PROTEIN; TRANSCRIPTION FACTOR ETS;

B CELL LEUKEMIA; EDITORIAL; GENE FUSION; GENE IDENTIFICATION; GENE TRANSLOCATION; HUMAN; MYELOPROLIFERATIVE DISORDER; TREATMENT RESPONSE; CHROMOSOME ABERRATION; CHRONIC MYELOMONOCYTIC LEUKEMIA; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; NOTE; REMISSION;

CHROMOSOME ABERRATIONS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MYELOPROLIFERATIVE DISORDERS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-ETS; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; REMISSION INDUCTION; REPRESSOR PROTEINS; TRANSLOCATION, GENETIC;

EID: 33947492782     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.11187     Document Type: Editorial

References (21)

1. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 1994;77:307-16.
2. Romana SP, Poirel H, Leconiat M, Flexor MA, Mauchauffe M, Jonveaux P, et al. High frequency of t(12;21) in childhood B-lineage acute lymphoblastic leukemia. Blood 1995;86:4263-9.
3. Walz C, Metzegeroth G, Haferlach C, Schmitt-Graeff A, Fabarius A, Hagen V, et al. Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor β gene. Haematologica 2007;92:163-9.
4. Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, Baxter EJ, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor β. N Engl J Med 2002;347:481-7.
5. Peeters P, Raynaud SD, Cools J, Wlodarska I, Grosgeorge J, Philip P, et al. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 1997;90:2535-40.
6. Papadopoulos P, Ridge SA, Boucher CA, Stocking C, Wiedemann LM. The novel activation of ABL by fusion to an ets-related gene, TEL. Cancer Res 1995;55:34-8.
7. Eguchi M, Eguchi-Ishimae M, Tojo A, Morishita K, Suzuki K, Sato Y, et al. Fusion of ETV6 to neurotrophin-3 receptor TRKC in acute myeloid leukemia with t(12;15)(p13;q25). Blood 1999;93:1355-63.
8. Vu HA, Xinh PT, Masuda M, Motoji T, Toyoda A, Sakaki Y, et al. FLT3 is fused to ETV6 in a myeloproliferative disorder with hypereosinophilia and a t(12;13)(p13;q12) translocation. Leukemia 2006;20:1414-21.
9. Golub TR, Barker GF, Bohlander SK, Hiebert SW, Ward DC, Bray-Ward P, et al. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci USA 1995; 92:4917-21.
10. Peeters P, Wlodarska I, Baens M, Criel A, Selleslag D, Hagemeijer A, Van den Berghe H, et al. Fusion of ETV6 to MDS1/EVI1 as a result of t(3;12)(q26;p13) in myeloproliferative disorders. Cancer Res 1997;57:564-9.
11. Buijs A, Van Rompaey L, Molijn AC, Davis JN, Vertegaal AC, Potter MD, et al. The MN1-TEL fusion protein, encoded by the translocation (12;22)(p13;q11) in myeloid leukemia, is a transcription factor with transforming activity. Mol Cell Biol 2000;20:9281-93.
12. Sabaawy HE, Azuma M, Embree LJ, Tsai HJ, Starost MF, Hickstein DD. TEL-AML1 transgenic zebrafish model of precursor B cell acute lymphoblastic leukemia. Proc Natl Acad Sci USA 2006;103:15166-71.
13. Janssen H, Wlodarska I, Mecucci C, Hagemeijer A, Vandenberghe P, Marynen P, et al. Fusion of ETV6 to GOT1 in a case with myelodysplastic syndrome and t(10;12)(q24;p13). Haematologica 2006;91:949-51.
14. Odero MD, Vizmanos JL, Roman JP, Lahortiga I, Panizo C, Calasanz MJ,et al. A novel gene, MDS2, is fused to ETV6/TEL in a t(1;12)(p36.1;p13) in a patient with myelodysplastic syndrome. Genes Chromosomes Cancer 2002; 35:11-9.
15. Cools J, Mentens N, Odero MD, Peeters P, Wlodarska I, Delforge M, et al. Evidence for position effects as a variant ETV6-mediated leukemogenic mechanism in myeloid leukemias with a t(4;12)(q11-q12;p13) or t(5;12)(q31;p13). Blood 2002;99:1776-84.
16. Barjesteh van Waalwijk van Doorn-Khosrovani S, Spensberger D, de Knegt Y, de Knegt Y, Tang M, Lowenberg B, et al. Somatic heterozygous mutations in ETV6 (TEL) and frequent absence of ETV6 protein in acute myeloid leukemia. Oncogene 2005;24:4129-37.
17. Bohlander SK. ETV6: a versatile player in leukemogenesis. Semin Cancer Biol 2005;15:162-74.
18. Cools J. The hypereosinophilic syndrome: idiopathic or not, that is the question. Haematologica 2005;90:582-4.
19. Stover EH, Chen J, Folens C, Lee BH, Mentens N, Marynen P, et al. Activation of FIP1L1-PDGFRα requires disruption of the juxtamembrane domain of PDGFRα and is FIP1L1-independent. Proc Natl Acad Sci USA 2006;103:8078-83.
20. Stover EH, Chen J, Lee BH, Cools J, McDowell E, Adelsperger J, et al. The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRβ and FIP1L1-PDGFRα in vitro and in vivo. Blood 2005; 106:3206-13.
21. Lierman E, Lahortiga I, Van Miegroet E, Mentens N, Marynen P, Cools J. The ability of sorafenib to inhibit oncogenic PDGFRβ and FLT3 mutants and overcome resistance to other small molecule inhibitors. Haematologica 2007;92: 27-34.